Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM) will provide a corporate update and engage in one-on-one investor meetings at the virtual Ladenburg Thalmann 2021 Healthcare Conference on July 13-14, 2021. The company is focused on developing therapies for rare genetic mitochondrial diseases, notably REN001, which aims to enhance ATP production by modulating key metabolic genes. REN001 has demonstrated potential in improving mitochondrial function and fatty acid oxidation.

News Market Reaction – RPHM

-1.82%

-1.82% Session move

In the trading session that priced this news, RPHM declined 1.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com

FAQ

What is Reneo Pharmaceuticals' focus in the healthcare sector?

Reneo Pharmaceuticals is focused on developing therapies for rare genetic mitochondrial diseases.

When is Reneo Pharmaceuticals participating in the Ladenburg Thalmann Healthcare Conference?

Reneo Pharmaceuticals will participate in the conference on July 13-14, 2021.

What is REN001 and its significance in Reneo Pharmaceuticals' portfolio?

REN001 is a therapy being developed by Reneo Pharmaceuticals to modulate genes critical for ATP production and mitochondrial function.

How does REN001 impact mitochondrial function?

REN001 has shown the ability to increase transcription of genes involved in mitochondrial function and enhance fatty acid oxidation.

What stock symbol is associated with Reneo Pharmaceuticals?

The stock symbol for Reneo Pharmaceuticals is RPHM.